News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
727,277 Results
Type
Article (49351)
Company Profile (314)
Press Release (677612)
Section
Business (212101)
Career Advice (2090)
Deals (36506)
Drug Delivery (98)
Drug Development (83487)
Employer Resources (169)
FDA (16916)
Job Trends (15678)
News (358875)
Policy (34617)
Tag
Academia (2758)
Alliances (51428)
Alzheimer's disease (1340)
Approvals (16875)
Artificial intelligence (176)
Bankruptcy (366)
Best Places to Work (12059)
Biotechnology (216)
Breast cancer (212)
Cancer (1555)
Cardiovascular disease (127)
Career advice (1751)
Cell therapy (313)
Clinical research (66838)
Collaboration (579)
Compensation (305)
COVID-19 (2675)
C-suite (139)
Data (1485)
Diabetes (191)
Diagnostics (6406)
Earnings (87146)
Employer resources (147)
Events (115313)
Executive appointments (483)
FDA (17708)
Funding (523)
Gene therapy (219)
GLP-1 (668)
Government (4609)
Healthcare (19825)
Infectious disease (2775)
Inflammatory bowel disease (119)
Interviews (317)
IPO (16754)
Job creations (4041)
Job search strategy (1497)
Layoffs (442)
Legal (8423)
Lung cancer (230)
Manufacturing (220)
Medical device (14229)
Medtech (14234)
Mergers & acquisitions (20006)
Metabolic disorders (520)
Neuroscience (1716)
NextGen: Class of 2025 (6905)
Non-profit (4732)
Northern California (1874)
Obesity (301)
Opinion (199)
Parkinson's disease (109)
Patents (133)
People (59467)
Phase I (20778)
Phase II (29373)
Phase III (21946)
Pipeline (614)
Postmarket research (2742)
Preclinical (8841)
Radiopharmaceuticals (249)
Rare diseases (290)
Real estate (6290)
Regulatory (23194)
Research institute (2474)
Resumes & cover letters (359)
Southern California (1622)
Startups (3821)
United States (16923)
Vaccines (614)
Weight loss (219)
Date
Today (28)
Last 7 days (664)
Last 30 days (1944)
Last 365 days (35694)
2025 (1600)
2024 (36150)
2023 (41147)
2022 (52385)
2021 (57106)
2020 (55920)
2019 (48807)
2018 (36940)
2017 (33751)
2016 (33576)
2015 (39611)
2014 (33325)
2013 (28560)
2012 (30847)
2011 (31556)
2010 (29926)
Location
Africa (789)
Arizona (211)
Asia (40535)
Australia (6675)
California (4263)
Canada (1554)
China (365)
Colorado (197)
Connecticut (214)
Europe (87660)
Florida (599)
Georgia (154)
Illinois (445)
Indiana (245)
Maryland (709)
Massachusetts (3331)
Michigan (187)
Minnesota (325)
New Jersey (1199)
New York (1213)
North Carolina (841)
Northern California (1874)
Ohio (153)
Pennsylvania (1000)
South America (1182)
Southern California (1622)
Texas (622)
Utah (122)
Washington State (440)
727,277 Results for "acuity medical inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis
Oculis Holding AG announced the completion of enrollment in its multi-center, randomized, double-blind, placebo-controlled Phase 2 ACUITY trial evaluating the safety and tolerability of OCS-05 in patients with Acute Optic Neuritis.
May 8, 2024
·
7 min read
Press Releases
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
January 6, 2025
·
15 min read
Drug Development
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
OpRegen ® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit.
May 6, 2024
·
11 min read
Press Releases
Piccolo Medical, Inc. Announces Distribution Agreement with Spectrum Vascular
January 13, 2025
·
2 min read
Drug Development
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
Ocuphire Pharma, Inc. today announced the enrollment of the first subject in the LYNX-2 Phase 3 registration study evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the treatment of decreased visual acuity under low (mesopic) light conditions following keratorefractive surgery.
April 11, 2024
·
9 min read
Press Releases
Boston Scientific Announces Agreement to Acquire Bolt Medical, Inc.
January 8, 2025
·
7 min read
Press Releases
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
January 15, 2025
·
1 min read
Press Releases
Stryker commences tender offer for all outstanding shares of common stock of Inari Medical, Inc.
January 17, 2025
·
6 min read
Press Releases
CardioSight, Inc appoints Niv Ad, M.D. as Chief Medical Officer
December 30, 2024
·
3 min read
Press Releases
Avanos Medical, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
·
1 min read
1 of 72,728
Next
